Revenue, last quarter
$132K
−93.9% vs same quarter last year
Net income
−$50M
−571.5% vs same quarter last year
EPS, diluted
−$4.74
−113.5% vs same quarter last year
Operating cash flow
−$10.1M
−11.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $27.5M | −$26.6M |
| FY24 | $9.3M | −$40.7M |
| FY23 | $5.5M | −$50.7M |
| FY22 | $1.2M | −$53M |
| FY21 | $14.9M | −$44.2M |
| FY20 | $3.2M | −$44.8M |
| FY19 | $3.5M | −$36.7M |
| FY18 | $1.1M | −$39M |
| FY17 | - | −$23.2M |
| FY16 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −96.7% | −96.9% |
| FY24 | −446.9% | −438% |
| FY23 | −949.9% | −924.1% |
| FY22 | −4275.1% | −4257.8% |
| FY21 | −292.6% | −295.6% |
| FY20 | −1428% | −1419.8% |
| FY19 | −1063.2% | −1061.2% |
| FY18 | −3386.7% | −3411.5% |
| FY17 | - | - |
| FY16 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$21.9M |
| FY24 | −$36.4M |
| FY23 | −$40M |
| FY22 | −$42M |
| FY21 | −$39.8M |
| FY20 | −$33.1M |
| FY19 | −$30.8M |
| FY18 | −$28.3M |
| FY17 | −$13.2M |
| FY16 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | $0 |
| FY22 | $200K |
| FY21 | $750.1K |
| FY20 | $271.1K |
| FY19 | $91K |
| FY18 | - |
| FY17 | - |
| FY16 | - |
- Cue Biopharma
- Healthcare median
Show the numbers
| Year | Cue Biopharma | Healthcare median |
|---|---|---|
| FY25 | −96.9% | −30.6% |
| FY24 | −438% | −47% |
| FY23 | −924.1% | −58% |
| FY22 | −4257.8% | −80.4% |
| FY21 | −295.6% | −71.9% |
| FY20 | −1419.8% | −62.2% |
| FY19 | −1061.2% | −46.3% |
| FY18 | −3411.5% | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |